@article{Marie José Kersten_Julia Driessen_Josée M. Zijlstra_Wouter J. Plattel_Franck Morschhauser_Pieternella J. Lugtenburg_Pauline Brice_Martin Hutchings_Thomas Gastinne_Roberto Liu_Coreline N. Burggraaff_Marcel Nijland_Sanne H. Tonino_Anne I.J. Arens_Roelf Valkema_Harm van Tinteren_Marta Lopez-Yurda_Arjan Diepstra_Daphne De Jong_Anton Hagenbeek_2021, place={Pavia, Italy}, title={Combining brentuximab vedotin with dexamethasone, high-dose cytarabine and cisplatin as salvage treatment in relapsed or refractory Hodgkin lymphoma: the phase II HOVON/LLPC Transplant BRaVE study}, volume={106}, url={https://haematologica.org/article/view/9712}, DOI={10.3324/haematol.2019.243238}, abstractNote={<p>Achieving a metabolic complete response (mCR) before high-dose chemotherapy (HDC) and autologous peripheral blood stem-cell transplant (auto-PBSCT) predicts progression free survival (PFS) in relapsed/refractory classical Hodgkin lymphoma (R/R cHL). We added brentuximab vedotin (BV) to DHAP to improve the mCR rate. In a Phase I dose-escalation part in 12 patients, we showed that BV-DHAP is feasible. This Phase II study included 55 R/R cHL patients (23 primary refractory). Treatment consisted of three 21-day cycles of BV 1.8 mg/kg on day 1, and DHAP (dexamethasone 40mg days 1-4, cisplatin 100mg/m2; day 1 and cytarabine 2x2g/m2; day 2). Patients with a metabolic partial response (mPR) or mCR proceeded to HDC/auto-PBSCT. Based on independent central FDG-PET-CT review, 42 of 52 evaluable patients (81% [95% CI: 67-90]) achieved an mCR before HDC/auto-PBSCT, five had an mPR and five had progressive disease (three were not evaluable). After HDC/auto-PBSCT, four patients with an mPR converted to an mCR. The 2-year PFS was 74% [95% CI: 63-86], and the overall survival 95% [95% CI: 90-100]. Toxicity was manageable and mainly consisted of grade 3/4 hematological toxicity, fever, nephrotoxicity, ototoxicity (grade 1/2) and transiently elevated liver enzymes during BV-DHAP. Eighteen patients developed new onset peripheral neuropathy (maximum grade 1/2) and all recovered. In conclusion, BV-DHAP is a very effective salvage regimen in R/R cHL patients, but patients should be monitored closely for toxicity. ClinicalTrials.gov identifier: <a class="external-ref external-ref-type-clintrialgov" href="/lookup/external-ref?link_type=CLINTRIALGOV&amp;access_num=NCT02280993&amp;atom=%2Fhaematol%2Fearly%2F2020%2F04%2F08%2Fhaematol.2019.243238.atom">NCT02280993</a>.</p&gt;}, number={4}, journal={Haematologica}, author={Marie José Kersten and Julia Driessen and Josée M. Zijlstra and Wouter J. Plattel and Franck Morschhauser and Pieternella J. Lugtenburg and Pauline Brice and Martin Hutchings and Thomas Gastinne and Roberto Liu and Coreline N. Burggraaff and Marcel Nijland and Sanne H. Tonino and Anne I.J. Arens and Roelf Valkema and Harm van Tinteren and Marta Lopez-Yurda and Arjan Diepstra and Daphne De Jong and Anton Hagenbeek}, year={2021}, month={Apr.}, pages={1129-1137} }